CCM
OMIC

CAAS Capital Management’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

CAAS Capital Management’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$336K – 1101
2021
Q3 		$336K Hold
1,000
– – 0.01% 682
2021
Q2 		$824K Buy
+1,000
New +$775K 0.01% 632

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAAS Capital Management's OMIC Position: Q4 2021 in Review

CAAS Capital Management sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q4 2021, closing a stake of 1,000 shares — an estimated $336K sold.

CAAS Capital Management first reported a position in OMIC in Q2 2021 and held it in 2 quarters. The position peaked at $824K in Q2 2021. 62 funds tracked by Wall St. Rank hold OMIC as of Q4 2021.

  • CAAS Capital Management reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 1,000 Singular Genomics Systems, Inc. Common Stock shares in Q4 2021, an estimated $336K.
  • CAAS Capital Management first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Singular Genomics Systems, Inc. Common Stock position peaked at $824K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.